44 results
8-K/A
EX-99.2
LSTA
Lisata Therapeutics Inc
4 Oct 22
Other Events
4:42pm
foreign regulatory authority may conclude that a financial relationship between Cend and a principal investigator has created a conflict of interest
8-K
EX-10.2
e85 yt664b7py7
15 Sep 22
Caladrius Biosciences and Cend Therapeutics Announce Closing of Merger and the Emergence of Lisata Therapeutics
9:16am
424B3
xitr1de5
29 Jul 22
Prospectus supplement
4:06pm
8-K
EX-10.1
y8m7 ahh96bm2nlabf
4 Jun 21
Entry into a Material Definitive Agreement
4:44pm
8-K
EX-10.2
55ycpgefh
25 Jan 21
Caladrius Biosciences Announces $25.0 Million Private Placement
4:01pm
8-K
EX-10.2
ujor t912
10 Jul 20
Entry into a Material Definitive Agreement
4:41pm
8-K
EX-10.2
5v9yk32 z3ub5cvm
26 May 20
Caladrius Biosciences Announces $4.3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
8:02am
8-K
EX-10.2
j6eaz5dl6rygps09
24 Apr 20
Caladrius Biosciences Announces $5.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
4:02pm